Jonathan Graff-Radford

List of Publications by Year
in descending order

207	8,477	41258	66788
papers	citations	49 h-index	78 g-index

208	208	208	8606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. Journal of Neurology, 2022, 269, 1427-1438.	1.8	9
2	Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611.	0.4	20
3	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.4	88
4	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
5	Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign. Journal of Alzheimer's Disease, 2022, 86, 491-498.	1.2	8
6	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Communications, 2022, 4, fcac017.	1.5	12
7	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
8	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
9	Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12291.	1.2	30
10	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
11	Posterior cortical atrophy: Primary occipital variant. European Journal of Neurology, 2022, 29, 2138-2143.	1.7	7
12	Dysexecutive Alzheimerâ€™s Disease with Lewy Body Disease Co-Pathology. Current Alzheimer Research, 2022, 19, 330-333.	0.7	0
13	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
14	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging. NeuroImage, 2022, 251, 119020.	2.1	9
15	Time in therapeutic range of anticoagulation among patients with atrial fibrillation and cerebral amyloid angiopathy. Baylor University Medical Center Proceedings, 2022, 35, 162-167.	0.2	0
16	Exercise and Brain Health. Neurology, 2022, 98, 825-826.	1.5	0
17	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	3.9	3
18	Author Response: Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2022, 98, 644-644.	1.5	0

#	Article	IF	Citations
19	Investigating Heterogeneity and Neuroanatomic Correlates of Longitudinal Clinical Decline in Atypical Alzheimer Disease. Neurology, 2022, 98, .	1.5	12
20	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
21	Artificial Intelligenceâ€“Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	1.4	6
22	PET Imaging of Dementia. Clinical Nuclear Medicine, 2022, 47, 763-773.	0.7	7
23	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
24	Performance of plasma phosphorylated tau 181 and 217 in the community. Nature Medicine, 2022, 28, 1398-1405.	15.2	114
25	Neuropathologic scales of cerebrovascular disease associated with diffusion changes on MRI. Acta Neuropathologica, 2022, 144, 1117-1125.	3.9	11
26	Polygenic Scores of Alzheimerâ€™s Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden. Journal of Alzheimer's Disease, 2022, 88, 1615-1625.	1.2	2
27	Population-Based Prevalence of Infarctions on 3D Fluid-Attenuated Inversion Recovery (FLAIR) Imaging. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106583.	0.7	5
28	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	1.6	44
29	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
30	Functional outcome after critical illness in older patients: a population-based study. Neurological Research, 2021, 43, 103-109.	0.6	7
31	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
32	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
33	Prevalence and Trends in Management of Idiopathic Normal Pressure Hydrocephalus in the United States: Insights from the National Inpatient Sample. World Neurosurgery, 2021, 145, e38-e52.	0.7	10
34	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
35	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
36	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5

#	Article	IF	Citations
37	Coping with brain amyloid: genetic heterogeneity and cognitive resilience to Alzheimerâ€™s pathophysiology. Acta Neuropathologica Communications, 2021, 9, 48.	2.4	18
38	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.4	18
39	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	4.9	214
40	Screening and management of atrial fibrillation in primary care. BMJ, The, 2021, 373, n379.	3.0	9
41	White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline. Brain Communications, 2021, 3, fcab076.	1.5	13
42	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	2.8	31
43	Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition. Brain Communications, 2021, 3, fcab106.	1.5	38
44	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
45	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
46	CSF dynamics as a predictor of cognitive progression. NeuroImage, 2021, 232, 117899.	2.1	3
47	Lipidomic Network of Mild Cognitive Impairment from the Mayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2021, 81, 533-543.	1.2	3
48	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	1.8	5
49	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphereâ€“Predominant Logopenic Progressive Aphasia. Neurology, 2021, 97, e523-e534.	1.5	4
50	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
51	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
52	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
53	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
54	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. Neurology, 2021, 97, 908-909.	1.5	7

#	Article	IF	Citations
55	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	4.5	114
56	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. American Heart Journal, 2021, 239, 73-79.	1.2	21
57	Response to â€œLetter to the editor concerning "High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus" by Naylor et al. (Clinical Neurology and Neurosurgery) Tj ETQq1 1 0.784314 rgBT /Overloc 2021, 208, 106820.	0.6	0
58	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
59	Artificial Intelligence-Enabled ECG to Identify Silent Atrial Fibrillation in Embolic Stroke of Unknown Source. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105998.	0.7	19
60	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	2.1	15
61	Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease. Neurobiology of Aging, 2021, 108, 90-98.	1.5	11
62	Cognitive Impairment in Patients with Stroke. Seminars in Neurology, 2021, 41, 075-084.	0.5	16
63	Longitudinal deterioration of white-matter integrity: heterogeneity in the ageing population. Brain Communications, 2021, 3, fcaa238.	1.5	11
64	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	1.2	2
65	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	1.5	7
66	White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12269.	1.2	1
67	Executive Dysfunction and the Prefrontal Cortex. CONTINUUM Lifelong Learning in Neurology, 2021, 27, 1586-1601.	0.4	44
68	Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimer's Research and Therapy, 2021, 13, 199.	3.0	32
69	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
70	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
71	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
72	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31

#	Article	IF	Citations
73	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
74	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
75	Utility of HAS-BLED and CHA2DS2-VASc Scores Among Patients With Atrial Fibrillation and Imaging Evidence of Cerebral Amyloid Angiopathy. Mayo Clinic Proceedings, 2020, 95, 2090-2098.	1.4	13
76	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
77	Predictors of adverse outcomes and cost after surgical management for idiopathic normal pressure hydrocephalus: Analyses from a national database. Clinical Neurology and Neurosurgery, 2020, 197, 106178.	0.6	10
78	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
79	Reduced fractional anisotropy of the genu of the corpus callosum as a cerebrovascular disease marker and predictor of longitudinal cognition in MCI. Neurobiology of Aging, 2020, 96, 176-183.	1.5	27
80	Variants inPPP2R2BandIGF2BP3are associated with higher tau deposition. Brain Communications, 2020, 2, fcaa159.	1.5	12
81	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.2	6
82	High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus. Clinical Neurology and Neurosurgery, 2020, 197, 106099.	0.6	6
83	Network Localization of Alien Limb in Patients with Corticobasal Syndrome. Annals of Neurology, 2020, 88, 1118-1131.	2.8	11
84	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	1.2	7
85	Artificial Intelligenceâ€“Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	2.1	68
86	High Mortality Rates Among Patients With Nonâ€Traumatic Intracerebral Hemorrhage and Atrial Fibrillation on Antithrombotic Therapy Are Independent of the Presence of Cerebral Amyloid Angiopathy: Insights From a Populationâ€Based Study. Journal of the American Heart Association, 2020, 9, e016893.	1.6	5
87	Expanded genetic insight and clinical experience of DNMT1-complex disorder. Neurology: Genetics, 2020, 6, e456.	0.9	7
88	Automated Hippocampal Subfield Volumetric Analyses in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 927-937.	1.2	14
89	Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2785-2793.	1.1	7
90	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	1.4	5

#	Article	IF	Citations
91	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
92	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
93	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
94	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
95	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in PRNP: the next generation. Neurocase, 2020, 26, 211-219.	0.2	4
96	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
97	Our Efforts in Understanding Normal Pressure Hydrocephalus: Learning from the 100 Most Cited Articles by Bibliometric Analysis. World Neurosurgery, 2020, 137, 429-434.e13.	0.7	7
98	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
99	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
100	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
101	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
102	Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease. Human Brain Mapping, 2019, 40, 1618-1631.	1.9	53
103	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
104	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Agingâ€“Alzheimerâ€™s Association Research Framework. JAMA Neurology, 2019, 76, 1174.	4.5	182
105	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
106	Exposure to surgery under general anaesthesia and brain magnetic resonance imaging changes in older adults. British Journal of Anaesthesia, 2019, 123, 808-817.	1.5	13
107	Association of Apolipoprotein E É›4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909.	2.8	41
108	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. Annals of Neurology, 2019, 86, 866-877.	2.8	40

#	Article	IF	Citations
109	Incidence of Convexal Subarachnoid Hemorrhage in the Elderly: The Mayo Clinic Study of Aging. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 104451.	0.7	1
110	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€tau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.4	38
111	Population-Based Evaluation of Lumbar Puncture Opening Pressures. Frontiers in Neurology, 2019, 10, 899.	1.1	25
112	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
113	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
114	Elevated Plasma Ceramides Are Associated With Higher White Matter Hyperintensity Volumeâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2431-2436.	1.1	8
115	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
116	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
117	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
118	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
119	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
120	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
121	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101823.	1.4	54
122	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	3.7	72
123	The role of age on tau PET uptake and gray matter atrophy in atypical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 675-685.	0.4	36
124	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
125	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
126	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22

#	Article	IF	Citations
127	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
128	¹⁸Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
129	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
130	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
131	Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Frontiers in Aging Neuroscience, 2019, 11, 355.	1.7	25
132	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
133	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
134	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
135	Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1713-1724.	1.2	45
136	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	2.8	73
137	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
138	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
139	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
140	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. Mayo Clinic Proceedings, 2018, 93, 145-154.	1.4	53
141	[¹⁸F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
142	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
143	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
144	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309

#	Article	IF	Citations
145	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
146	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
147	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
148	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
149	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
150	Cognitive dysfunction in atrial fibrillation. Nature Reviews Cardiology, 2018, 15, 744-756.	6.1	73
151	Statins and Brain Health: Alzheimerâ€™s Disease and Cerebrovascular Disease Biomarkers in Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1345-1352.	1.2	23
152	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
153	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
154	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
155	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
156	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. JAMA Neurology, 2017, 74, 718.	4.5	107
157	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
158	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	4.5	68
159	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	0.7	93
160	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
161	Caudate nucleus as a component of networks controlling behavior. Neurology, 2017, 89, 2192-2197.	1.5	62
162	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162

#	Article	IF	Citations
163	Age, vascular health, and Alzheimer disease biomarkers in an elderly sample. Annals of Neurology, 2017, 82, 706-718.	2.8	136
164	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
165	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
166	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. Neurology, 2017, 89, 2039-2048.	1.5	15
167	Cerebral Amyloid Angiopathy. Journal of the American College of Cardiology, 2017, 70, 1173-1182.	1.2	73
168	Cerebral amyloid angiopathy and implications for atrial fibrillation management. Lancet, The, 2017, 390, 9-11.	6.3	16
169	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
170	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
171	¹⁸F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. Journal of Nuclear Medicine, 2017, 58, 632-638.	2.8	91
172	[O4â€“04â€“05]: CEREBRAL MICROBLEEDS AND AMYLOID BURDEN: THE MAYO CLINIC STUDY OF AGING. Alzheimer's and Dementia, 2017, 13, P1237.	0.4	0
173	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
174	P2â€201: Pathologic Predictors of Disease Duration in Lewy Body Disease. Alzheimer's and Dementia, 2016, 12, P698.	0.4	0
175	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
176	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
177	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
178	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
179	Mediodorsal nucleus and its multiple cognitive functions. Neurology, 2016, 87, 2161-2168.	1.5	40
180	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32

#	Article	IF	Citations
181	Cascading network failure across the Alzheimerâ€™s disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
182	The clinical relevance of cerebral microbleeds in patients with cerebral ischemia and atrial fibrillation. Journal of Neurology, 2016, 263, 238-244.	1.8	27
183	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
184	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
185	Structured handoff checklists improve clinical measures in patients discharged from the neurointensive care unit. Neurology: Clinical Practice, 2015, 5, 42-49.	0.8	16
186	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
187	History of Hollenhorst Plaques. Stroke, 2015, 46, e82-4.	1.0	6
188	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
189	Neuroimaging and clinical features in type II (late-onset) Alexander disease. Neurology, 2014, 82, 49-56.	1.5	71
190	Fluorodeoxyglucose F18 positron emission tomography in a case of slowly progressive pure alexia. Neurocase, 2014, 20, 476-479.	0.2	0
191	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
192	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
193	The neuroanatomy of pure apraxia of speech in stroke. Brain and Language, 2014, 129, 43-46.	0.8	83
194	Transient Amnesia After Coiling of a Posterior Circulation Aneurysm. Neurocritical Care, 2013, 18, 245-247.	1.2	16
195	A Neurological Complication of a Uterine Fibroid. Neurocritical Care, 2013, 18, 93-95.	1.2	4
196	The alien limb phenomenon. Journal of Neurology, 2013, 260, 1880-1888.	1.8	75
197	Magnetic resonance spectroscopy in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 2013, 9, 687.	1.0	61
198	Fluorodeoxyglucose F18 PET in progressive emotional dysprosody. Neurology, 2012, 79, 480-481.	1.5	2

#	Article	IF	Citations
199	Progressive Multifocal Leukoencephalopathy in a Patient Treated With Etanercept. Neurologist, 2012, 18, 85-87.	0.4	21
200	Primary Progressive Aphasia and Transient Global Amnesia. Archives of Neurology, 2012, 69, 401.	4.9	18
201	Parkinsonian motor features distinguish the agrammatic from logopenic variant of primary progressive aphasia. Parkinsonism and Related Disorders, 2012, 18, 890-892.	1.1	30
202	Limb immobilization and corticobasal syndrome. Parkinsonism and Related Disorders, 2012, 18, 1097-1099.	1.1	2
203	Extramedullary tumors and leukemia. Neurology, 2012, 79, 85-91.	1.5	3
204	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
205	Clinical and Radiologic Correlations of Central Pontine Myelinolysis Syndrome. Mayo Clinic Proceedings, 2011, 86, 1063-1067.	1.4	95
206	Focal brain atrophy in gastric bypass patients with cognitive complaints. Journal of Clinical Neuroscience, 2011, 18, 1671-1676.	0.8	8
207	Dopamine agonists and Othelloâ€™s syndrome. Parkinsonism and Related Disorders, 2010, 16, 680-682.	1.1	21